Document is current
Any future updates will be listed below
-
Authors
Becht, Kelly
Lindsay, Meghan E.
Soulos, Pamela R.
Singh, Charu
Hansen, James E.
An, Yi
Aneja, Sanjay
Goldberg, Sarah B.
Chiang, Veronica L.
Park, Henry S.
-
Funding
Funding for this research was provided by:
Yale Cancer Center
- License Information
-
More Information
Article History
Received: 22 March 2026
Accepted: 8 May 2026
First Online: 15 May 2026
Declarations
:
: This study is approved for IRB exemption (Protocol ID: 2000035458).
: The data used in this study is derived from de-identified SEER database Participant User Files. This study is approved for IRB exemption with waiver of informed consent.
: James E. Hansen: Patrys Ltd (patents, consulting, research funding, stock/options). Sarah B. Goldberg: Amgen (consulting, advisory board), AstraZeneca (consulting, advisory board, research funding), Boehringer Ingelheim (research funding), Bristol-Myers Squibb (consulting, advisory board), Daiichi-Sankyo (consulting, advisory board), Eli Lilly (consulting, advisory board), Janssen (consulting, advisory board), Merck (consulting, advisory board), Mirati (research funding), Regeneron (consulting, advisory board), Sanofi Genzyme (consulting, advisory board), Summit Therapeutics (consulting, advisory board), Takeda (consulting, advisory board). Henry S. Park: AstraZeneca (consulting, advisory board), Bristol Myers Squibb (speaking fees/honoraria), Curio Sciences (consulting), G1 Therapeutics (speaking fees/honoraria), Galera Medical (advisory board), Merck (research funding), Regeneron Pharmaceuticals (advisory board), RefleXion Medical (research funding, consulting). No additional disclosures from other authors related to the following research.
